Drug Type Biological products |
Synonyms NN/sTNF-R1, sTNF R1 |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | Preclinical | United States | 05 Dec 2023 | |
Brain Cancer | Preclinical | United States | 05 Dec 2023 | |
Breast Cancer | Preclinical | United States | 05 Dec 2023 | |
Colorectal Cancer | Preclinical | United States | 05 Dec 2023 | |
Esophageal Carcinoma | Preclinical | United States | 05 Dec 2023 | |
Hodgkin's Lymphoma | Preclinical | United States | 05 Dec 2023 | |
Liver Cancer | Preclinical | United States | 05 Dec 2023 | |
Lung Cancer | Preclinical | United States | 05 Dec 2023 | |
Melanoma | Preclinical | United States | 05 Dec 2023 | |
MRSA - Methicillin resistant Staphylococcus aureus infection | Preclinical | United States | 05 Dec 2023 |